Notably, patients presenting with IL-6 ≥ 2000 pg mL−1 enjoyed a 17% absolute survival gain—echoing the biologic heterogeneity emphasised in recent precision-sepsis frameworks and suggesting that inflammatory-load enrichment may be essential to demonstrate benefit in future trials. The gene discussed is IL6; the disease is Sepsis.